Dr. Mandal is developing new technologies that identify the shape of proteins that could provide new targets for cancer immunotherapy, with potential applications to other diseases.
Dr. Mamedov is using gene-editing technologies to create a new platform for understanding an important set of immune cells that may provide the keys to the diagnosis, prevention, and treatment of infectious and non-communicable diseases such as cancer.
Dr. Sahu is building novel artificial-intelligence (AI) deep-learning frameworks to devise new therapeutic strategies for cancer immunotherapy, with potential applications in human immunology.
Dr. MacKay is studying recently described subset of immune cells called tissue resident memory T cells, which combat various viral infections and cancer. The research that will be funded by the Prize will examine immune responses by tissue resident memory T cells to harness their protective functions to improve vaccines and immunotherapies.
Dr. Satpathy is focused on combining disciplines of genomics and human immunology. His research will identify key gene regulatory mechanisms that trigger protective immunity following vaccination using novel epigenomic sequencing technologies applied directly to patient samples. The Prize will allow him to greatly accelerate his work, advancing both 3D and single-cell epigenetic technologies to human immunology and vaccine research.
Dr. Illing was the first to identify spliced peptides during a viral infection. This work involves an innovative new approach for identifying influenza-specific peptide antigens with implications for the development of vaccines against both seasonal and pandemic influenza strains. The Prize money will provide greater resources to expand understanding of how a viral antigen is recognized by the human immune system.